We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

IGM Biosciences Inc (IGMS) USD0.01

Sell:$18.18 Buy:$18.33 Change: $0.64 (3.38%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.64 (3.38%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.64 (3.38%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

IGM Biosciences, Inc. is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The Company has created an IgM antibody technology platform for developing T cell engagers, receptor cross-linking agonists, targeted cytokines and target neutralizers. Its product candidates in clinical testing include IGM-2323 and IGM-8444. IGM-2323 is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in a Phase II clinical trial for the treatment of relapsed/refractory B cell non-Hodgkins lymphoma (NHL) patients. IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) proteins for the treatment of patients with solid and hematologic malignancies, is in a Phase I clinical trial for the treatment of solid cancers. Its oncology pipeline also includes IGM-7354, IGM-2644 and IGM-2537.

Contact details

325 E Middlefield Rd
United States
+1 (650) 9657873

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$818.64 million
Shares in issue:
42.53 million
United States
US dollar

Key personnel

  • Fred Schwarzer
    President, Chief Executive Officer, Director
  • Misbah Tahir
    Chief Financial Officer
  • Bruce Keyt
    Chief Scientific Officer
  • Lisa Decker
    Chief Business Officer
  • George Gauthier
    Chief Commercial Officer
  • Chris Takimoto
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.